1. Scrip code : 500189
Name : NXTDIGITAL LIMITED
Subject : Corporate Action-Updates on Amalgamation/ Merger / Demerger
Further to our letter dated July 15, 2020, towards intimation of the final hearing scheduled on July 28, 2020, towards the scheme of arrangement between IndusInd Media & Communications Limited and NXTDIGITAL LIMITED and their respective shareholders by which Media and Communication undertaking of IMCL will be demerged into the Company. In this regard, we would like to inform you that the National Company Law Tribunal, Mumbai Bench has approved the aforesaid scheme today, August 6, 2020. On receipt of a copy of the final order of the Hon’ble NCLT, as soon as received, we will submit the same to the exchanges. Consequent to this order and filing of the order with the Ministry of Corporate Affairs all listing formalities are expected to be completed within the month of August 2020. The intimation of the date of the Board meeting to declare the restated accounts for March 31, 2020 consequent to merger and Q 1 results on the merged basis in August 2020 will be communicated separately.
2. Scrip code : 509079
Name : Gufic BioSciences Ltd.
Subject : Shareholder Meeting / Postal Ballot-Court Convened Meeting On September 15, 2020
Pursuant to Regulation 30 read with Schedule III of SEBI(Listing Obligations And Disclosure Requirements) Regulations, 2015, we wish to inform that in accordance with the order dated July 14, 2020 passed by the National Company Law Tribunal, Mumbai bench under sub-section (1) of Section 230 of the Companies Act, 2013, the Meeting of the Equity Shareholders of the Company is scheduled to be held on Tuesday, September 15, 2020 at 12.30 p.m. through video conferencing or other audio visual means (‘VC/ OAVM’), following the operating procedures (with requisite modifications as may be required) for the purpose of considering, and if thought fit, approving with or without modification(s), the proposed Scheme of Amalgamation (Merger by Absorption) of Gufic Lifesciences Private Limited (‘Transferor Company’) with Gufic Biosciences Limited (‘Transferee Company’)